This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.
Back
Understanding Lebrikizumab for Atopic Dermatitis in Skin of Color
A multipart video series featuring perspectives from leading experts in dermatology on the role of lebrikizumab (Ebglyss) in patients with atopic dermatitis and skin of color.
Understanding Lebrikizumab for Atopic Dermatitis in Skin of Color
Episodes
All
All
This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.
This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.
This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.
This interview with Andrew Alexis, MD, MPH, highlights his team’s findings in the phase 3b ADmirable trial on lebrikizumab for atopic dermatitis in patients with skin of color.
The report highlights lebrikizumab’s potential for sustained disease modification and its evolving role in long-term atopic dermatitis management.
In this report, Chovatiya highlights lebrikizumab’s evolving role in long-term atopic dermatitis management.
Advertisement
Advertisement
Trending on HCPLive
1
Brensocatib Patient Selection Evolves 1 Year After FDA Approval
2
CKM Syndrome, Artery Damage Prevalence Higher in Young Adults than Previously Believed
3
ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD
4
The HCPFive: Top News for Healthcare Providers from the Week of 08/16
5